Scientists may be closing in on two major advances in the fight against Lyme disease: an overlooked antibiotic that eliminates the infection at exceptionally low doses and new insights into why symptoms often persist long after treatment.
In a pair of studies published recently in Science Translational Medicine, scientists showed that piperacillin—a Food and Drug Administration-approved antibiotic—cleared Lyme infections in mice at doses up to 100 times lower than those of doxycycline, the current first-line treatment.
